BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg 2019;3:130-7. [PMID: 30923782 DOI: 10.1002/ags3.12225] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Ajina R, Zahavi DJ, Zhang YW, Weiner LM. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. Semin Cancer Biol 2020;65:28-37. [PMID: 31866479 DOI: 10.1016/j.semcancer.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mejia I, Bodapati S, Chen KT, Díaz B. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines 2020;8:E401. [PMID: 33050151 DOI: 10.3390/biomedicines8100401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Labib PL, Yaghini E, Davidson BR, MacRobert AJ, Pereira SP. 5-Aminolevulinic acid for fluorescence-guided surgery in pancreatic cancer: Cellular transport and fluorescence quantification studies. Transl Oncol 2021;14:100886. [PMID: 33059124 DOI: 10.1016/j.tranon.2020.100886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Gautam SK, Kumar S, Dam V, Ghersi D, Jain M, Batra SK. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Semin Immunol 2020;47:101391. [PMID: 31952903 DOI: 10.1016/j.smim.2020.101391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
5 Malinova A, Veghini L, Real FX, Corbo V. Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Front Cell Dev Biol 2021;9:795251. [PMID: 34926472 DOI: 10.3389/fcell.2021.795251] [Reference Citation Analysis]
6 Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer 2021;1876:188554. [PMID: 33945847 DOI: 10.1016/j.bbcan.2021.188554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Monteiro MV, Gaspar VM, Mendes L, Duarte IF, Mano JF. Stratified 3D Microtumors as Organotypic Testing Platforms for Screening Pancreatic Cancer Therapies. Small Methods 2021;5:e2001207. [PMID: 34928079 DOI: 10.1002/smtd.202001207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Aronen A, Aittoniemi J, Huttunen R, Nikkola A, Rinta-Kiikka I, Nikkola J, Limnell O, Nordback I, Sand J, Laukkarinen J. Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer. Scand J Gastroenterol 2021;56:81-5. [PMID: 33245246 DOI: 10.1080/00365521.2020.1849383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Tarannum M, Holtzman K, Dréau D, Mukherjee P, Vivero-Escoto JL. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer. J Control Release 2022:S0168-3659(22)00281-4. [PMID: 35569588 DOI: 10.1016/j.jconrel.2022.05.019] [Reference Citation Analysis]
10 Mesquita G, Prevarskaya N, Schwab A, Lehen'kyi V. Role of the TRP Channels in Pancreatic Ductal Adenocarcinoma Development and Progression. Cells 2021;10:1021. [PMID: 33925979 DOI: 10.3390/cells10051021] [Reference Citation Analysis]
11 Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther 2020;5:249. [PMID: 33122631 DOI: 10.1038/s41392-020-00341-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
12 Wang Q, Zhu X, Wu Z, Sun T, Huang W, Wang Z, Ding X, Jiang C, Li F. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. J Mater Chem B 2020;8:2410-7. [PMID: 32100811 DOI: 10.1039/d0tb00017e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Popov AB, Melle F, Linnane E, González-López C, Ahmed I, Parshad B, Franck CO, Rahmoune H, Richards FM, Muñoz-Espín D, Jodrell DI, Fairen-Jimenez D, Fruk L. Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer. Nanoscale 2022. [PMID: 35438701 DOI: 10.1039/d2nr00864e] [Reference Citation Analysis]
14 Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, Piemonti L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers (Basel) 2021;13:4442. [PMID: 34503252 DOI: 10.3390/cancers13174442] [Reference Citation Analysis]
15 Yang CY, Fan MH, Miao CH, Liao YJ, Yuan RH, Liu CL. Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer. Mol Ther Oncolytics 2020;17:571-85. [PMID: 32637575 DOI: 10.1016/j.omto.2020.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
16 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wrona E, Potemski P, Sclafani F, Borowiec M. Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer. Arch Immunol Ther Exp (Warsz) 2021;69:2. [PMID: 33630157 DOI: 10.1007/s00005-021-00605-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vera RE, Fernandez-Zapico ME. Stromal deactivation by CSF1: a new feature of the aggressive pancreatic cancer microenvironment. EMBO Rep 2020;21:e50468. [PMID: 32329185 DOI: 10.15252/embr.202050468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol 2020;17:940-53. [PMID: 32699350 DOI: 10.1038/s41423-020-0505-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
20 Delma MI. Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma? Cureus 2020;12:e10909. [PMID: 33194476 DOI: 10.7759/cureus.10909] [Reference Citation Analysis]
21 Heinrich MA, Mostafa AMRH, Morton JP, Hawinkels LJAC, Prakash J. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev 2021;174:265-93. [PMID: 33895214 DOI: 10.1016/j.addr.2021.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Buoncervello M, Gabriele L, Toschi E. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. Int J Mol Sci 2019;20:E4320. [PMID: 31484464 DOI: 10.3390/ijms20174320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
23 Zheng X, Liu X, Zheng H, Wang H, Hong D. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma. Int Immunopharmacol 2021;90:106982. [PMID: 33129696 DOI: 10.1016/j.intimp.2020.106982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Nweke EE, Naicker P, Aron S, Stoychev S, Devar J, Tabb DL, Omoshoro-Jones J, Smith M, Candy G. SWATH-MS based proteomic profiling of pancreatic ductal adenocarcinoma tumours reveals the interplay between the extracellular matrix and related intracellular pathways. PLoS One 2020;15:e0240453. [PMID: 33048956 DOI: 10.1371/journal.pone.0240453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kang Y, Datta P, Shanmughapriya S, Ozbolat IT. 3D Bioprinting of Tumor Models for Cancer Research. ACS Appl Bio Mater 2020;3:5552-73. [DOI: 10.1021/acsabm.0c00791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
26 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Tarannum M, Vivero-escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2022.114357] [Reference Citation Analysis]
28 Nsingwane Z, Candy G, Devar J, Omoshoro-Jones J, Smith M, Nweke E. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. Mol Biol Rep 2020;47:6269-80. [PMID: 32661873 DOI: 10.1007/s11033-020-05648-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Fujimoto T, Tsunedomi R, Matsukuma S, Yoshimura K, Oga A, Fujiwara N, Fujiwara Y, Matsui H, Shindo Y, Tokumitsu Y, Suzuki N, Kobayashi S, Hazama S, Eguchi H, Nagano H. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Oncol Lett 2021;21:30. [PMID: 33240436 DOI: 10.3892/ol.2020.12291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tassone E, Muscolini M, van Montfoort N, Hiscott J. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment? Cytokine Growth Factor Rev 2020;56:141-8. [PMID: 32859494 DOI: 10.1016/j.cytogfr.2020.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135-e145. [PMID: 32135117 DOI: 10.1016/s1470-2045(19)30795-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
32 Marques P, Silva AL, López-Presa D, Faria C, Bugalho MJ. The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary 2022. [PMID: 35194709 DOI: 10.1007/s11102-022-01211-5] [Reference Citation Analysis]
33 Delle Cave D, Rizzo R, Sainz B Jr, Gigli G, Del Mercato LL, Lonardo E. The Revolutionary Roads to Study Cell-Cell Interactions in 3D In Vitro Pancreatic Cancer Models. Cancers (Basel) 2021;13:930. [PMID: 33672435 DOI: 10.3390/cancers13040930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Nagalo BM, Breton CA, Zhou Y, Arora M, Bogenberger JM, Barro O, Steele MB, Jenks NJ, Baker AT, Duda DG, Roberts LR, Russell SJ, Peng KW, Borad MJ. Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. Mol Ther Oncolytics 2020;18:546-55. [PMID: 32839735 DOI: 10.1016/j.omto.2020.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Ayres Pereira M, Chio IIC. Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes (Basel) 2019;11:E6. [PMID: 31861620 DOI: 10.3390/genes11010006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
36 Qin JJ, Cheng XD, Zhang J, Zhang WD. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. Cell Commun Signal 2019;17:121. [PMID: 31511020 DOI: 10.1186/s12964-019-0435-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
37 Pednekar KP, Heinrich MA, van Baarlen J, Prakash J. Novel 3D µtissues Mimicking the Fibrotic Stroma in Pancreatic Cancer to Study Cellular Interactions and Stroma-Modulating Therapeutics. Cancers (Basel) 2021;13:5006. [PMID: 34638490 DOI: 10.3390/cancers13195006] [Reference Citation Analysis]
38 Lambin T, Lafon C, Drainville RA, Pioche M, Prat F. Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma. World J Gastroenterol 2022; 28(13): 1288-1303 [DOI: 10.3748/wjg.v28.i13.1288] [Reference Citation Analysis]
39 Kole C, Charalampakis N, Tsakatikas S, Frountzas M, Apostolou K, Schizas D. Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights. CMAR 2022;Volume 14:1043-61. [DOI: 10.2147/cmar.s267260] [Reference Citation Analysis]
40 Bai RL, Wang NY, Zhao LL, Zhang YF, Cui JW. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00169-7. [PMID: 34538570 DOI: 10.1016/j.hbpd.2021.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tan HNC, Catedral LIG, San Juan MD. Prognostic Significance of Tumor-infiltrating Lymphocytes on Survival Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. J Immunother 2021;44:29-40. [PMID: 32909965 DOI: 10.1097/CJI.0000000000000331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Kane S, Engelhart A, Guadagno J, Jones A, Usoro I, Brutcher E. Pancreatic Ductal Adenocarcinoma: Characteristics of Tumor Microenvironment and Barriers to Treatment. J Adv Pract Oncol 2020;11:693-8. [PMID: 33575066 DOI: 10.6004/jadpro.2020.11.7.4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhang L, Wang W, Wang R, Zhang N, Shang H, Bi Y, Chen D, Zhang C, Li L, Yin J, Zhang H, Cao Y. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma. Mol Ther 2021;29:744-61. [PMID: 33130310 DOI: 10.1016/j.ymthe.2020.10.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
44 Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D. Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep 2021;36:109578. [PMID: 34433022 DOI: 10.1016/j.celrep.2021.109578] [Reference Citation Analysis]
45 Mottini C, Cardone L. Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers. Int J Mol Sci 2020;21:E5023. [PMID: 32708716 DOI: 10.3390/ijms21145023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Su T, Yang B, Gao T, Liu T, Li J. Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. Ther Adv Med Oncol 2020;12:1758835920915978. [PMID: 32426046 DOI: 10.1177/1758835920915978] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]